Literature DB >> 2973118

Influence of cryptococcal antigens on cell-mediated immunity.

J W Murphy1.   

Abstract

Cryptococcosis is a frequently fatal disease caused by a yeast-like organism, Cryptococcus neoformans. Patients with systemic cyptococcosis generally have cryptococcal antigen in their body fluids; levels of antigen directly correlate with severity of the disease. With use of a murine model, it was documented that cell-mediated immunity is an important protective mechanism and that an epitope(s) on the mannoprotein fraction of the cryptococcal antigen present in a culture filtrate is recognized in cell-mediated immunity. Sera from mice infected with C. neoformans will induce suppressor cells that suppress cell-mediated immunity, as measured by the delayed-type hypersensitivity response, and the level of cryptococcal antigen in the serum directly correlates with the degree of suppression induced. There is no correlation with the amount of anticryptococcal antibody and the ability of the serum to induce suppression. Further, it was demonstrated that cryptococcal antigen, when injected into mice at concentrations similar to those found in human systemic cryptococcosis, induces a complex series of suppressor cells and factors that specifically suppress the delayed-type hypersensitivity response and protective immunity to cryptococci.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2973118     DOI: 10.1093/cid/10.supplement_2.s432

Source DB:  PubMed          Journal:  Rev Infect Dis        ISSN: 0162-0886


  28 in total

Review 1.  A yeast under cover: the capsule of Cryptococcus neoformans.

Authors:  Indrani Bose; Amy J Reese; Jeramia J Ory; Guilhem Janbon; Tamara L Doering
Journal:  Eukaryot Cell       Date:  2003-08

2.  Early induction of interleukin-12 by human monocytes exposed to Cryptococcus neoformans mannoproteins.

Authors:  L Pitzurra; R Cherniak; M Giammarioli; S Perito; F Bistoni; A Vecchiarelli
Journal:  Infect Immun       Date:  2000-02       Impact factor: 3.441

3.  Pathogenesis of Cryptococcus neoformans in congenitally immunodeficient beige athymic mice.

Authors:  C A Salkowski; E Balish
Journal:  Infect Immun       Date:  1990-10       Impact factor: 3.441

4.  Size Matters: Measurement of Capsule Diameter in Cryptococcus neoformans.

Authors:  Tiffany Guess; Hoyin Lai; Serenah E Smith; Linda Sircy; Kirsten Cunningham; David E Nelson; Erin E McClelland
Journal:  J Vis Exp       Date:  2018-02-27       Impact factor: 1.355

5.  Purification and characterization of a second immunoreactive mannoprotein from Cryptococcus neoformans that stimulates T-Cell responses.

Authors:  Chao Huang; Shu-Hua Nong; Michael K Mansour; Charles A Specht; Stuart M Levitz
Journal:  Infect Immun       Date:  2002-10       Impact factor: 3.441

6.  Protective efficacy of antigenic fractions in mouse models of cryptococcosis.

Authors:  Michael K Mansour; Lauren E Yauch; James B Rottman; Stuart M Levitz
Journal:  Infect Immun       Date:  2004-03       Impact factor: 3.441

7.  Characterization of the PMT gene family in Cryptococcus neoformans.

Authors:  Sven D Willger; Joachim F Ernst; J Andrew Alspaugh; Klaus B Lengeler
Journal:  PLoS One       Date:  2009-07-27       Impact factor: 3.240

8.  Encapsulation of Cryptococcus neoformans impairs antigen-specific T-cell responses.

Authors:  H L Collins; G J Bancroft
Journal:  Infect Immun       Date:  1991-11       Impact factor: 3.441

9.  Isolation and purification of antigenic components of Cryptococcus.

Authors:  Karen L Wozniak; Stuart M Levitz
Journal:  Methods Mol Biol       Date:  2009

10.  Mouse-human immunoglobulin G1 chimeric antibodies with activities against Cryptococcus neoformans.

Authors:  S L Zebedee; R K Koduri; J Mukherjee; S Mukherjee; S Lee; D F Sauer; M D Scharff; A Casadevall
Journal:  Antimicrob Agents Chemother       Date:  1994-07       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.